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Abstract Cyclosporin A (CsA) is a widely used immunosup-
pressive agent with severe side effects including hypertension.
Here, we investigated the effects of CsA on intracellular free
calcium ([Ca2+]i) and the mechanisms involved in vasoconstric-
tion in cultured human coronary myocytes. We used the Fura-2
technique for Ca2+ imaging. Acute application of CsA at
therapeutic concentrations (0.1^10 Wmol/l) had no effect.
Chronic exposure to CsA (1 Wmol/l) for 24 h induced a small
(20 nmol/l) but highly significant increase of basal [Ca2+]i and
enhanced the occurrence of spontaneous Ca2+ oscillations.
Endothelin- and vasopressin-induced rises of [Ca2+]i were also
enhanced. The demonstration that CsA increases basal [Ca2+]i in
addition to its impact on agonist receptor stimulation is of major
importance for new therapeutic approaches. ß 2001 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Cyclosporin A (CsA) is the most commonly used immuno-
suppressive drug used after organ transplantation and in the
treatment of a variety of autoimmune diseases [1]. Vasocon-
striction induced by CsA results in major side e¡ects including
arterial hypertension [2] and renal failure [3]. Direct intracoro-
nary injection of CsA induces a vasoconstrictive response
through endothelium-dependent and myogenic mechanisms
in the dog coronary artery [4,5]. Possible mechanisms include
a direct increase of blood vessel tonus [6], stimulation of the
renin^angiotensin system [7], increased production of vaso-
constrictor agents such as thromboxane A2 [8] and endothe-
lin-1 (ET) [9,10], up-regulation of ET [11], vasopressin (AVP)
[12] or angiotensin II receptors [13], increases in the phosphor-
ylation of speci¢c contractile regulatory proteins [14] or, yet,
reduced production of vasodilating agents such as prostacy-
clins [15] and nitric oxide [16]. Thus, an alteration of both
endothelium-dependent and -independent vasodilating re-
sponses may be involved [4,17]. Since contraction of vascular
smooth muscle cells (VSMCs) depends on intracellular calci-
um ([Ca2]i), the measurements of the e¡ect of CsA on [Ca2]i
have been performed in rat [12,18^21] and human [13] aortic
cells but diverging results were shown. However, there is a
lack of information concerning the e¡ect of CsA on [Ca2]i
in coronary myocytes. We investigated the e¡ects of CsA on
[Ca2]i in cultured human coronary myocytes.
2. Material and methods
2.1. Myocyte isolation and culture
Tissue samples were obtained from coronary arteries of six Cauca-
sian male patients (18^60 years) undergoing heart transplantation
over a period of 18 months. Patients had end-stage heart failure
(New York Heart Association, classes III and IV) caused by idio-
pathic cardiomyopathy. Arteries were devoid of pathology (in partic-
ular atheroma). The procedures were approved by the Ethical Com-
mittee of the Hospital. Cells were isolated and grown in culture as
described before [22^24]. Brie£y, arteries were collected after cardiec-
tomy. Media were incubated for 50 min at 37‡C in Hanks’ solution
containing 1 mg/ml collagenase (Worthington, Newark, NJ, USA)
and 0.6 mg/ml elastase (Boehringer, Mannheim, Germany) and then
dispersed. Next, the cells were centrifuged (100Ug, 7 min) and resus-
pended in a medium for VSMCs (Clonetics Bio-Whittaker, Emerain-
ville, France) containing: gentamicin sulfate 25 Wg/ml, amphotericin
25 ng/ml, human ¢broblast growth factor 2 ng/ml, bovine insulin
5 Wg/ml, human epidermal growth factor 0.5 ng/ml and fetal bovine
serum 20%. Cells were then plated (10 000 cells/ml) in 25 cm3 dispos-
able £asks (Falcon) and placed at 37‡C in an air/CO2 incubator. The
medium was changed every day during the ¢rst week. Thereafter, the
cells were transferred to maintenance medium (Dulbecco’s minimum
essential medium and Ham’s F-10, 1:1 v/v; Eurobio, Les Ulis,
France) containing 5% human serum and 5% Myoclone Super Plus
(fetal bovine; Life Technologies, Cergy Pontoise, France) which was
changed every 2^3 days. Con£uence was reached 15^20 days after
plating. Then, cells were trypsinized and grown in LAB-TEK dishes
(Polylabo, Strasbourg, France). A total of 15 di¡erent cultures were
used. We tested one set of cells originating from a healthy 24 year old
Caucasian male (cells commercially available: Bio-Whittaker Europe,
Verviers, Belgium).
2.2. Dye loading and measurement of [Ca2+]i
The [Ca2]i was measured in single cells as described before [25].
Brie£y, the dual excitation radiometric Ca2-sensitive dye Fura-2 was
used for [Ca2]i imaging studies with an Olympus-LSR system (Mer-
lin; Life Science Resources Ltd, Cambridge, UK). The variations in
[Ca2]i were detected with the sensing £uorescent probe Fura-2 by
means of a digital CCD camera. Cells grown in LAB-TEK dishes
were loaded by incubation with 2.5 WM of the acetoxymethyl ester
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of Fura-2 and 0.02% Pluronic F-127 (Fura-2/AM and Pluronic, Mo-
lecular Probes Inc., Eugene, OR, USA) for 35 min at 37‡C in Locke
bu¡er containing (mmol/l): NaCl, 140; KCl, 5; KH2PO4, 1.2;
MgSO4, 1.2; CaCl2, 1.8; glucose, 10; HEPES, 10; pH 7.2 adjusted
with NaOH. The osmolarity of all the solutions ranged between 298
and 303 mosmol/l. Cells were then rinsed thoroughly in Locke bu¡er
and mounted on the stage of an inverted microscope (Olympus IX70;
Olympus France, Rungis, France) equipped for epi£uorescence. Illu-
mination was via a SpectraMASTER monochromator coupled to the
microscope ¢tted with a UV-transparent oil objective (Uapo/340 40U/
1.35). The image was detected with an Astrocam 12/14 bit frame
transfer digital camera. The MERLIN system controlled the illumi-
nator and camera, and performed image ratioing and analysis. The
image acquisition rate was 1.13 frames/s. The intensity of £uorescent
light emission at V= 510 nm, using excitation at 340 and 380 nm, was
monitored for each single Fura-2-loaded cell. The ratio of £uorescence
emission when excited at 340 nm (the absorbance peak of Fura bound
to Ca2) to 380 nm (the absorbance peak of free Fura) was used as an
index of [Ca2]i, with an increase in the £uorescence ratio (FR340=380)
signifying an increase in [Ca2]i. In order to estimate absolute varia-
tions, the [Ca2]i was calculated from the ratio, in accordance with the
equation given by Grynkiewicz et al. [26]. Fura-2 calibration was
performed in ionomycin-treated (10 Wmol/l) cells incubated in the
presence and absence of external Ca2. The estimated [Ca2]i was
deduced from the equation: [Ca2] = KdB(R3Rmin)/(Rmax3R), where
Kd is the dissociation constant (225 nmol/l). The other variables were
readily accessible from the measurements performed in control cells
and in cells incubated with CsA. Rmin and Rmax are the 340/380 ratios
of the Ca2-free (i.e. when the dye is free of Ca2 with 10 mmol/l
EGTA added) and Ca-bound (5 mM Ca2) forms, respectively. The
variability in Rmin (range 0.4^0.6) and Rmax (range 1.4^1.6) ratios was
independent of the presence or absence of CsA; this is common, even
in supposedly homogeneous cell populations. B is the ratio of £uores-
cence excitation intensities of the two latter forms at 380 nm (F380min/
F380max).
2.3. Drugs
Crystallized pure CsA (Novartis Pharma, Basel, Switzerland), was
prepared daily with a ¢rst dilution of 1.5 mg in 250 Wl pure sterile
dimethyl sulfoxide (DMSO) leading to 5 mmol/l ¢nal concentration.
Further dilutions to 10 Wmol/l and 1 Wmol/l were performed with the
standard Locke solution. Then, the ¢nal DMSO concentration in the
cell medium was less than 0.1%. ET (Sigma, Saint Quentin Fallavier,
France) was aliquoted at 100 Wmol/l in 10 Wl of acetic acid (5%).
[Arg8]vasopressin (AVP; Calbiochem-Novabiochem, La«ufel¢ngen,
Switzerland) was aliquoted at 1 mmol/l in 10 Wl deionized H2O, and
then frozen at 380‡C. The high K solution contained the following
(in mmol/l) : NaCl, 90; KCl, 50; KH2PO4, 1.2; MgSO4, 1.2; CaCl2,
1.8; glucose, 10; HEPES, 10; pH 7.2 adjusted with NaOH. In most
experiments, sequences of image acquisition lasted for 4^5 min in
order to avoid the decrease in £uorescence (fading) induced by repet-
itive irradiation during longer experiments. Acute (20^30 s), extracel-
lular application of the test agonists (KCl, CsA, ET, AVP) was
achieved using a multiple capillary gravity-driven perfusion system
(200 Wm inner diameter; 100 Wl/min) placed in close proximity
(6 0.5 mm) to each group of cells studied (3^10 cells in each experi-
ment). Following each application, cells were washed with Locke bu¡-
er. For chronic exposure to CsA, cells grown in the LAB-TEKs were
incubated with 1 Wmol/l CsA for 24 h prior to experiments.
2.4. Analyses
Since some cells exhibited spontaneous oscillatory activity, the ef-
fects of agonists were analyzed only in cells devoid of spontaneous
oscillations of [Ca2]i after a 2 min period of observation. In addition,
in order to detect any spontaneous, drug-unrelated increase of [Ca2]i
occurring during application of agonists, we estimated the delay ob-
served between the time of application and the onset of the various
responses (on average: 3.2 þ 0.2 s, n = 12, for KCl; 7.3 þ 0.2 s, n = 19,
for ET; and 18.2 þ 2.5 s, n = 12, for AVP). The duration of the re-
sponses were also examined. Spontaneous oscillations were analyzed
in cells recorded for at least 5 min in the absence of prior application
of any drug. For each cohort of cells used, changes in FR340=380
following exposure to the test agent(s) were compared to the matched
baseline values by either paired Student’s t-test or unpaired t-test
(with Welch’s correction when variances were not equal). All values
are reported as mean þ S.E.M. Results were considered not signi¢cant
(ns) with Ps 0.05, signi¢cant with 0.016P6 0.05, very signi¢cant
with 0.0016P6 0.01 and extremely signi¢cant with P6 0.001. Statis-
tical analysis was performed with SAS statistical software (SAS In-
stitute, Inc., Cary, NC, USA).
3. Results
First, [Ca2]i was measured at rest and in response to the
depolarizing cation K (KCl) and the two vasoconstrictive
agents AVP and ET on cells devoid of spontaneous oscillatory
activity of [Ca2]i. Addition of K (KCl 50 mmol/l) induced a
transient increase of [Ca2]i (Fig. 1A) in all cells tested
(n = 12). On average, K increased the £uorescence ratio
FR340=380 from 0.76 þ 0.01 to 1.23 þ 0.01. ET, at a concentra-
tion of 100 nmol/l, induced an all-or-none response (i.e. in-
ducing no measurable increase or alternatively, only a large
increase). There was a rise of the FR340=380 in 76% of the cells
(n = 54) which is illustrated in Fig. 1B. On average, the
FR340=380 was increased from 0.74 þ 0.01 to 1.03 þ 0.02. Sim-
ilarly, AVP (100 nmol/l) induced a rise in [Ca2]i in 53% of
the cells (n = 17). This e¡ect is illustrated in Fig. 1C. On aver-
age, the FR340=380 was increased from 0.73 þ 0.01 to
0.98 þ 0.03.
Next, we evaluated the e¡ect of acute application of CsA
on [Ca2]i. CsA was applied for 20^30 s at 0.1, 1, or 10 Wmol/
l, and then, after wash-out, cells were exposed to ET, AVP, or
K. The results showed that CsA had neither signi¢cant e¡ect
in 65 out of 69 cells analyzed at any of the concentrations
tested nor when the drug was applied for a longer time (10
min). Four myocytes responded to CsA (6%) with only a
moderate increase (FR340=380 less than 0.88). The majority of
cells that were not responsive to acutely applied CsA re-
sponded to AVP (Fig. 2A), ET (100 nmol/l) or to depolariza-
tion by 50 mM K (data not shown).
The consequences of 24 h exposure to CsA (0.1 and 1 Wmol/
l) were also assessed in a cohort of myocytes (n = 442; from
seven di¡erent cultures). We compared the basal [Ca2]i after
24 h incubation to the baseline value of [Ca2]i in control cells
(n = 338). To avoid undesirable non-speci¢c culture e¡ects,
time-matched control experiments were conducted in which
test and control cells were grown in parallel from the same
tissue samples. Thus test and control experiments were per-
formed randomly. The results showed that the resting [Ca2]i
was increased signi¢cantly after pre-incubation with 1 WM
CsA (no e¡ect at 0.1 Wmol/l). On average, the basal
FR340=380 was increased very signi¢cantly from 0.758 þ 0.003
to 0.791 þ 0.003 (P6 0.01) as shown in Fig. 2B. After calibra-
tion in an attempt to estimate the variation in terms of abso-
lute value (see Section 2), this corresponded to an extremely
signi¢cant increase in basal [Ca2]i from 100 þ 2 nmol/l to
120 þ 2 nmol (P6 0.001). In addition, many cells chronically
exposed to CsA exhibited oscillatory activity with spontane-
ous increases of [Ca2]i (Fig. 2C). On average, the FR340=380
increased to 0.92 þ 0.03, corresponding to an estimated max-
imal increase of [Ca2]i to 210 þ 22 nmol/l, which was similar
to the average maximal increase observed during oscillations
in control cells (FR340=380 0.94 þ 0.01). There was also no sig-
ni¢cant di¡erence in the time course of these oscillations
which lasted, on average, 91 þ 7 s (n = 6) in control cells and
109 þ 7 s (n = 16) in CsA-treated cells. However, spontaneous
increases of [Ca2]i were detected in more cells from the pop-
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ulation of CsA-treated cells (35%, n = 119) than in the popu-
lation of control cells (7%, n = 83; P6 0.001 as determined
with Fisher’s exact test). Since there was no signi¢cant di¡er-
ence in oscillation frequency between the CsA-treated
(0.007 þ 0.0003 Hz, n = 16) and the control cells
(0.008 þ 0.0004 Hz, n = 6), CsA is likely to increase the num-
ber of cells with oscillatory activity rather than the frequency
of oscillations of a given cell. Similar results were observed in
cells originating from one normal heart. For example, the
basal FR340=380 increased from 0.793 þ 0.04 (n = 96) to
0.821 þ 0.04 (n = 42, P6 0.001) in those cells after pre-incuba-
tion with 1 WM CsA.
Next, we assessed the consequences of 24 h exposure to
CsA on the responses of [Ca2]i to ET and AVP (100 nmol/
l). Here also, time-matched control and test experiments were
conducted in parallel from the same tissue samples. The ef-
fects of ET and AVP were analyzed only in cells devoid of
spontaneous oscillations (a majority of cells) to minimize in-
terference. Furthermore, analysis of their delay, duration
helped us to distinguish drug-related and spontaneous in-
creases of [Ca2]i for the interpretation of the results. Fig.
3A,B illustrates the distinct e¡ects of ET on the FR340=380 in
control cells and in cells pre-incubated with 1 Wmol/l CsA. In
control cells, the mean basal £uorescence ratio rose from
0.76 þ 0.01 to a peak of 1.06 þ 0.02 (n = 71). In CsA-treated
cells, the ratio increased from 0.79 þ 0.01 to an absolute value
of 1.12 þ 0.02 (n = 35). The amplitude of the di¡erence (mean
peak ratio minus mean basal ratio) was very signi¢cantly
higher (0.35 þ 0.02) in the CsA-treated cells than in the control
group (0.27 þ 0.02; P6 0.01). We estimated that the augmen-
tation of [Ca2]i induced by ET was increased from 393 þ 43
Fig. 1. Representative FR340=380 traces of the increasing e¡ects of
(A) K (50 mmol/l), (B) ET (100 nmol/l), and (C) AVP (100 nmol/
l) on [Ca2]i in fura-2-loaded human coronary myocytes. Cells were
loaded with the Ca2 indicator and studied as described in Section
2. The time and duration of applications are represented by the hor-
izontal bars at the top of each panel. Experiments were conducted
on three di¡erent cells.
Fig. 2. E¡ect of CsA. A: Lack of e¡ect following acute exposure to
CsA (1 Wmol/l) on [Ca2]i in a Fura-2-loaded human coronary myo-
cyte. After wash-out of CsA, AVP (100 nmol/l) induced a rise in
[Ca2]i which was similar to that shown in Fig. 1. B: Bar graphs
show the mean increase in basal [Ca2]i induced by incubating hu-
man coronary myocytes with CsA (1 Wmol/l) for 24 h prior to the
experiments (**P6 0.01). C: Typical spontaneous increases in
[Ca2]i observed in a human coronary myocyte incubated with CsA
(1 Wmol/l) for 24 h prior to the experiment.
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nmol/l to 677 þ 161 nmol/l in CsA-treated cells (P6 0.01). The
time course of the response was markedly di¡erent from that
of spontaneous oscillations. For example, the increase in
[Ca2]i induced by ET lasted 200 þ 5 s (n = 29). Similar e¡ects
were observed with AVP (Fig. 4A,B). AVP increased the
mean basal £uorescence ratio from 0.73 þ 0.01 to a peak of
0.98 þ 0.03 in the control group of cells (n = 12) and from
0.81 þ 0.01 to 1.19 þ 0.02 in the CsA-incubated group
(n = 39). Again, the amplitude of di¡erence was extremely sig-
ni¢cantly higher (0.39 þ 0.02) in the incubated group than in
the control group (0.25 þ 0.02; P6 0.001). These results are
illustrated in Fig. 4A,B. We estimated that the augmentation
of [Ca2]i induced by AVP was increased from 277 þ 36 nmol/l
to 761 þ 62 nmol (P6 0.001) in CsA-treated cells. In contrast
with ET, the duration of the AVP response was not signi¢-
cantly di¡erent from that of spontaneous oscillations, due to
some variability in the duration among cells. However, the
amplitude of the rise in [Ca2]i was signi¢cantly higher than
the amplitude of spontaneous oscillations which excluded a
misinterpretation of the results. We found no di¡erence in
the number of cells that responded to ET and AVP after
incubation with CsA. Similar results were found for the cells
originating from the single donor devoid of pathology (data
not shown).
4. Discussion
Numerous studies have reported data on the many events
associated with development of arterial hypertension and
nephrotoxicity induced by CsA during therapeutic use. How-
ever, the exact mechanism(s) is (are) still unclear and there is
no satisfying therapy available to prevent side e¡ects. The
major ¢ndings of the present study are that, in human coro-
nary myocytes, CsA (i) has no acute e¡ect on [Ca2]i, (ii)
increases basal [Ca2]i moderately but signi¢cantly after 24
h exposure, (iii) increases the frequency of occurrence of spon-
taneous oscillatory activity of [Ca2]i, and (iv) potentiates the
e¡ects of ET and AVP, two potent vasoconstrictor hormones.
Coronary constriction has been shown in vivo after acute
exposure to CsA [4,6,17]. However, the mechanisms by which
this occurs are still not well understood. Some of the results
obtained on arterial rings are of little clinical interest due to
the high concentrations employed (40 Wmol/l^5 mmol/l) [5,14].
Although CsA has been reported to induce contraction of
isolated rat VSMCs, this e¡ect was suggested to be mediated
by ET [10]. We show here that acute application of clinically
relevant concentrations of CsA had no direct e¡ect on [Ca2]i
in cultured human coronary myocytes. However, these cells
responded to K depolarization which con¢rmed the presence
of functional Ca2 channels required for Ca2 entry [22] and
of an e¡ective coupling with intracellular stores involved in
the rise in [Ca2]i. In particular, a majority of cells responded
to AVP (53%) and ET (76%) with an all-or-nothing response
Fig. 3. E¡ect of chronic exposure to CsA (1 Wmol/l) for 24 h on the
ET-induced rise of [Ca2]i in cultured human coronary myocytes.
A: Illustration of the maximal e¡ect of ET as observed in two dif-
ferent cells incubated with and without CsA (1 Wmol/l) for 24 h pri-
or to the experiments. B: Bar graphs show the mean e¡ects of the
two conditions. The maximal increase in [Ca2]i induced by ET was
higher in cells incubated with CsA (*P6 0.05).
Fig. 4. E¡ect of chronic exposure to CsA (1 Wmol/l) for 24 h on the
AVP-induced rise of [Ca2]i in cultured human coronary myocytes.
A: Illustration of the maximal e¡ect of AVP as observed in two dif-
ferent cells incubated without and with CsA (1 Wmol/l) for 24 h pri-
or to the experiments. B: Bar graphs show the mean e¡ects of the
two conditions. The maximal increase in [Ca2]i induced by AVP
was higher in cells incubated with CsA (***P6 0.001).
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which also demonstrated that the major Ca2 signalling path-
ways were present at the population level despite some vari-
ability among cells and between the AVP and ET pathways.
Therefore, we hypothesize that the lack of e¡ect of acute
application of CsA on [Ca2]i was genuine. An indirect e¡ect,
mediated via the release of endothelial-derived contracting
factors [4,5], or also a possible direct e¡ect on contractile
protein activity of muscle cells [14], might explain the discrep-
ancy with some other studies performed in vivo or on arterial
rings in vitro.
Whether CsA promotes a signi¢cant rise in the resting
[Ca2]i of human arterial cells is of great interest because
this elevation may trigger a variety of signals. Our study
shows for the ¢rst time that therapeutic concentrations of
CsA applied for 24 h increase [Ca2]i in human arterial cells.
However, this ¢nding contrasts with a similar study in human
aortic cells [13]. The discrepancy may relate to the number of
cells used. The increase found in our study was indeed mod-
erate but proved highly signi¢cant due to the use of cohorts of
cells (for both control and test conditions).
Here, we show that chronic treatment with CsA has two
other major e¡ects. The ¢rst is to enhance the occurrence of
spontaneous short [Ca2]i rises, which di¡er from the larger
and more prolonged increases observed during agonist recep-
tor stimulation. This occurrence involves an increase in the
number of cells likely to generate oscillatory activity. This is
probably directly related to the elevation in the resting cyto-
solic [Ca2]i and the resulting periodic release of internally
stored Ca2. The second is to potentiate the increases in
[Ca2]i that are induced by AVP and ET in human coronary
myocytes. We suggest that these e¡ects may participate in
increased arterial blood pressure. This ¢nding extends similar
observations made before on hormone responses in rat aortic
myocytes where, in addition to AVP and ET, serotonin and
angiotensin II actions were shown to be also potentiated by
CsA [12,21] independently of its immunosuppressive e¡ect
and calcineurin inhibition [12,13,20,27]. It has been suggested
that CsA acts on a target upstream of G protein activation,
possibly at the receptor level [12]. In addition, it was shown
that the potentiation of angiotensin responses in human aortic
cells induced by therapeutic concentrations of CsA re£ects a
twofold increase in the number of angiotensin-1 receptors due
to an upregulation of these receptors [13,28^30]. The CsA-
induced increase in the resting [Ca2]i which we report here
is probably too weak to account per se for any change in the
basal tone of the artery. However, the resulting promotion of
spontaneous increases of [Ca2]i may contribute to the in-
crease in vasoconstriction. This contribution may be direct
as well as indirect since Ca2 oscillations have been shown
to increase both the e⁄cacy and the information content of
Ca2 signals in relation with activation of Ca2-dependent
genes [31,32]. Variations in the frequency and duration of
global Ca2 signals activate di¡erent genes [31,33]. Thus, re-
petitive increases in cytoplasmic Ca2, which are probably
related to increased periodic release of internally stored
Ca2, could up-regulate the synthesis (or activity) of receptor
proteins involved in vasoconstriction as shown for AVP [18].
This step may be a key event in enhanced vasoconstrictor
hormone action by CsA. To overcome the problem of the
side e¡ects of CsA, several therapeutic solutions have been
proposed including use of antagonists of ET receptors [34],
inhibitors of the renin^angiotensin system [35,36], Ca2 chan-
nel blockers [35^37], or restoration of NO-mediated vasodila-
tation by L-arginine [38]. However, these strategies provide
only partial bene¢ts. Further study of the mechanisms under-
lying the CsA-induced increase in [Ca2]i are clearly needed to
¢nd the putative pharmacological key point involved in trig-
gering the multiple e¡ects of the drug.
One limitation of this study may reside in the fact that,
though they were devoid of atheroma, the arteries from which
the cells derived were taken from pathological hearts (dilated
cardiomyopathy). However, it should be noted that the results
obtained with cells derived from one donor with a normal
heart were consistent. Another limitation may concern the
possible compartmentalization of the £uorescent Ca2 indica-
tor in some organelles (e.g. mitochondria, endoplasmic retic-
ulum, nucleus) rather than in the cytoplasm. Further work,
using for example confocal microscopy, is mandatory to local-
ize precisely the initial rise in [Ca2]i at the subcellular level
and to describe the mechanisms involved. Whatever the origin
of the spontaneous oscillations, however, their large ampli-
tude seems to be accounted for by variations of the cytosolic
[Ca2]i.
In conclusion, our results demonstrate that therapeutic con-
centrations of CsA lead to an elevation of the resting [Ca2]i
with promotion of spontaneous oscillatory activity and an
increased hormone-induced rise of [Ca2]i in human coronary
myocytes. Although the latter e¡ect occurs independently of
potential drug e¡ects on endothelium-dependent release of
hormones, it may contribute to the potentiation of those ef-
fects by increasing the sensitivity of myocytes to various hor-
mones. Hence, strategies aimed at reducing the side e¡ects of
CsA should not target a single hormone receptor. The dem-
onstration that CsA increases basal Ca2 upstream of its mul-
tiple e¡ects on di¡erent hormone receptors is worth consider-
ing for the development of new therapeutic approaches.
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